UBQLN4 and esophageal squamous cell carcinoma: For Co‐IPs, the ESCC cell lines were treated with cisplatin (to enhance the levels of ubiquitinated‐MRE11A and promote the interaction with UBQLN4) and with MG‐132 inhibitor (to block proteasomal degradation).